Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

32.51 +0.19 (+0.59%)

Streaming Delayed Price Updated: 2:36 PM EDT, May 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn

August 27, 2025

The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy...

Via MarketMinute

What Does the Market Think About Beam Therapeutics? ↗

August 25, 2025

Via Benzinga

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

August 25, 2025

From Beam Therapeutics

Via GlobeNewswire

Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease ↗

August 15, 2025

Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.

Via Benzinga

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

August 14, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

August 05, 2025

From Beam Therapeutics

Via GlobeNewswire

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential ↗

June 28, 2025

Via The Motley Fool

Topics Artificial Intelligence

Cathie Wood's Ark Invest Continues To Offload Coinbase, Bets Big On SoFi Technologies ↗

June 27, 2025

Cathie Wood-led Ark Invest made notable trades on Friday, including selling shares in Coinbase and Roblox.

Via Benzinga

The FDA Shake-Up Continues, And Could Impact Genetic Medicines ↗

June 20, 2025

Nicole Verdun and Rachael Anatol were placed on administration leave without explanation.

Via Investor's Business Daily

Topics Government

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst ↗

June 18, 2025

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Via Benzinga

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover ↗

June 17, 2025

The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments.

Via Investor's Business Daily

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

June 13, 2025

From Beam Therapeutics

Via GlobeNewswire

Cathie Wood's Ark Invest Continues To Offload Palantir, Loads Up On Beam Therapeutics, GitLab ↗

June 11, 2025

Via Benzinga

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

June 03, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 29, 2025

From Beam Therapeutics

Via GlobeNewswire

BioMedNewsBreaks — Beam Therapeutics Inc. (NASDAQ: BEAM) to Present New Sickle Cell Data from BEACON Trial at EHA2025

May 23, 2025

Via Investor Brand Network

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

May 14, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

May 13, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 12, 2025

From Beam Therapeutics

Via GlobeNewswire

10 Analysts Assess Beam Therapeutics: What You Need To Know ↗

May 07, 2025

Via Benzinga

Why Beam Therapeutics Stock Tanked on Tuesday ↗

May 06, 2025

Via The Motley Fool

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 06, 2025

From Beam Therapeutics

Via GlobeNewswire

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost ↗

April 21, 2025

The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.

Via Investor's Business Daily

Topics Government

Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday ↗

April 21, 2025

Via Benzinga

Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease ↗

April 07, 2025

Beam Therapeutics shared updated BEAM-302 trial data in AATD and plans U.S. site activation following FDA clearance of its IND

Via Benzinga

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

April 05, 2025

From Beam Therapeutics

Via GlobeNewswire

Cathie Wood's Ark Invest Loads Up On Amazon, Coinbase: Offloads UiPath, Roblox ↗

April 04, 2025

Via Benzinga

Cathie Wood Just Made A Bold Move—Why She Spent Over $65M On Tesla, Robinhood, And Coinbase 'As The Market Crashed' ↗

April 04, 2025

Via Benzinga

This Applied Materials Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗

March 28, 2025

Via Benzinga

Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock ↗

March 28, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.